OncoMatch/Clinical Trials/NCT01766297
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
Is NCT01766297 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for breast cancer.
The purpose of this research study is to compare the effects (good and bad) on women and their cancer using proton radiation therapy. This study is being done to see if proton radiation therapy will prove to be beneficial for women with early stage breast cancer. A clinical study is necessary to compare the results (good or bad) of proton radiation therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 positive
Must have ER positive disease with ER/PR report available.
Excluded: BRCA1 mutation
Known BRCA 1 or BRCA 2 mutation.
Excluded: BRCA2 mutation
Known BRCA 1 or BRCA 2 mutation.
Allowed: HER2 (ERBB2) tested (positive or negative is acceptable)
For tumors that are invasive, HER2 must be performed (positive or negative is acceptable).
Disease stage
Required: Stage 0, I, II
Prior therapy
Cannot have received: radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic · Scottsdale, Arizona
- California Protons Cancer Therapy Center · San Diego, California
- Northwestern Medicine Chicago Proton Center · Warrenville, Illinois
- Maryland Proton Treatment Center · Baltimore, Maryland
- McLaren Proton Therapy Center · Flint, Michigan
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify